A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 268 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Five Questions With…Fern, Christina, Mary, and Shelley. May 26, 2022 Worried Cancer Patients Face Delayed Treatment Because Of Pandemic April 1, 2020 Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or... March 18, 2025 For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target January 3, 2019 Load more HOT NEWS FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma Efficacy of Rituximab Maintenance in Patients with Mantle Cell Lymphoma Who... 20 Adorable Tiny Homes That Are Perfect For A Peaceful Weekend... Feasibility and Safety of Preoperative Treatment with Nivolumab and Relatlimab in...
